Adrian Gottschalk, Foghorn Therapeutics CEO (Flagship via YouTube)
June 28, 2023 11:11 AM EDT
R&D

With just one re­sponse in 47 pa­tients, Foghorn stops work on lead can­di­date in ad­vanced eye can­cer

Lei Lei Wu

News Reporter

Foghorn Ther­a­peu­tics said Wednes­day morn­ing that it was stop­ping fur­ther work on an ex­per­i­men­tal drug for a rare ad­vanced eye can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times